Exosomes Therapeutic Pipeline Assessment, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trial Activities, Emerging Therapies, Treatment Algorithm, and Key Companies by DelveInsight

As per DelveInsight's assessment, about 55+ prominent pharma and biotech giants are actively working on 70+ drugs in the Exosomes' therapeutics market globally.

Exosomes possess a higher therapeutic potential for various disease spectra due to their ability for intracellular shuttling. Nanomedicine technologies have given rise to exploring the usage of the pathogenic importance of exosomal particles in various diseases. The increase in the usage of exosomes is a direct consequence of the overall increase in the incident and prevalent population of the diseases where they are used, along with robust R&D leading to the introduction of new exosomes for therapeutic as well as diagnostic usage, accompanied by increasing availability of exosomes.

"Exosomes Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Exosomes Therapeutics Market.

The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Exosomes Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing Exosomes drugs.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development in the Exosomes segment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details in the Exosomes market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight's Report Covers the 70+ Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Exosomes Therapeutics Market Landscape
Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes contain several molecules such as microRNA (miRNA), which mediate biological functions by controlling the genes. Exosomes carrying miRNA or other molecules can, therefore, improve the therapeutic effects of various transplants that take place.

Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aiding in disease diagnosis. Extensive studies are going on to assess the role of exosomes in diagnosing and treating various pathologies. There are approx. 55+ key companies which are developing the Exosomes. Currently, Direct Biologics has its Exosomes drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Exosomes Market Landscape Include:
- Direct Biologics
- Capricor
- Regeneus
- AVEM HealthCare
- Aegle Therapeutics
- Organicell Regenerative Medicine
- Codiak Biosciences
- United Therapeutics
- ArunA Biomedical
- Evox Therapeutics
- MolecuVax
- Versatope Therapeutics
- Lamellar Biomedical
- Azymus Therapeutics
- Alxerion Biotech
- Avalon GloboCare
- Capricor Therapeutics
And many more

Exosomes Pipeline Products Covered in the Report Include
- ExoFlo: Direct Biologics
- Progenza: Regeneus
- AVA-201: Avalon GloboCare
- RGLS4326: Regulus Therapeutics Inc.
- exoIL-12: Codiak BioSciences
- DB-001: Direct Biologics, LLC
- AGLE 102: Aegle Therapeutics
- CAP-1002: Capricor Inc.
And many others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Introduction
2. Executive Summary
3. Exosomes: In-depth Overview
4. Pipeline Therapeutics & Comparative Analysis
5. Therapeutic Assessment
6. Exosomes - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment (Collaborations, Licensing/Partnering, Acquisition -Deal Value Trends)
8. Late-Stage Products (Phase III)
9. Mid-Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Pre-clinical and Discovery Stage Products
12. Inactive Products
13. Exosomes Key Companies
14. Exosomes Key Products
15. Exosomes Unmet Needs
16. Exosomes- Market Drivers and Barriers
17. Exosomes Future Perspectives and Conclusion
18. Exosomes Analyst Views
19. Appendix
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.